Detalles de la búsqueda
1.
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
BMC Genomics
; 17: 442, 2016 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27277198
2.
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
BMC Cancer
; 16: 34, 2016 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26801902
3.
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Tumour Biol
; 36(6): 4327-38, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25596703
4.
TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.
J Proteome Res
; 12(9): 4136-51, 2013 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23909892
5.
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Tumour Biol
; 34(2): 1161-70, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23334956
6.
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.
Tumour Biol
; 34(6): 3839-51, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23881388
7.
Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
BMC Cancer
; 13: 598, 2013 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24330623
8.
Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.
Histopathology
; 59(5): 975-83, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22092409
9.
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 121(2): 365-71, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19653096
10.
Banking of biological fluids for studies of disease-associated protein biomarkers.
Mol Cell Proteomics
; 7(10): 2061-6, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18676364
11.
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
BMC Cancer
; 9: 322, 2009 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19744322
12.
A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Tumour Biol
; 29(3): 181-7, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18645261
13.
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.
Scand J Gastroenterol
; 43(7): 774-86, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18584515
14.
TIMP-1 as a tumor marker in breast cancer--an update.
Acta Oncol
; 47(4): 580-90, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465326
15.
Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Clin Cancer Res
; 12(23): 7054-8, 2006 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17114213
16.
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Clin Cancer Res
; 10(7): 2289-98, 2004 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15073104
17.
Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Scand J Gastroenterol
; 43(2): 186-91, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18224564
18.
Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.
Mol Cell Proteomics
; 4(4): 483-91, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15640527
19.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Mol Cell Proteomics
; 2(3): 164-72, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12672830
20.
Tumor markers: from laboratory to clinical utility.
Mol Cell Proteomics
; 2(6): 378-87, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12813140
Resultados
1 -
20
de 20
1
Próxima >
>>